Identification | Back Directory | [Name]
PF-4942847 | [CAS]
1046859-34-0 | [Synonyms]
PF-4942847 PF-04942487 2-Amino-4-[2,4-dichloro-6-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]-5,7-dihydro-N-(2,2,2-trifluoroethyl)-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide 6H-Pyrrolo[3,4-d]pyrimidine-6-carboxamide, 2-amino-4-[2,4-dichloro-6-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]-5,7-dihydro-N-(2,2,2-trifluoroethyl)- 2-aMino-4-(2,4-dichloro-6-(2-(4-fluoro-4,5-dihydropyrazol-1-yl)ethoxy)phenyl)-N-(2,2,2-trifluoroethyl)-5H-pyrrolo[3,4-d]pyriMidine-6(7H)-carboxaMide | [Molecular Formula]
C20H18Cl2F3N7O2 | [MOL File]
1046859-34-0.mol | [Molecular Weight]
516.3 |
Hazard Information | Back Directory | [Uses]
A novel potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitor of heat shock protein 90 (Hsp90). It has been shown to induce degradation of multiple client proteins, cell-cycle block, apoptosis, and inhibits cell proliferation in triple-negative breast cancer (TNBC) lines, subsequently leading to tumor growth inhibition in mouse xenograft models. |
|
Company Name: |
NCE Biomedical Co.,Ltd.
|
Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0.htm |
Company Name: |
SPIRO PHARMA
|
Tel: |
|
Website: |
www.spiropharma.com.cn |
|